Forbes July 2, 2022
Last month, the Federal Trade Commission (FTC) voted unanimously (5-0) to examine rising list prices of insulin, but also to probe possible anti-competitive practices by pharmacy benefit managers (PBMs) with respect to the use of rebate arrangements. Rebates are payments from drug manufacturers to PBMs in exchange for moving market share towards preferred products on the formulary. The FTC cites instances in which cheaper generics and biosimilars are excluded from PBM formularies, as this may violate competition and consumer protection laws.
Separately, in early June, the FTC opened an investigation into six large PBMs. The FTC also voted unanimously (5-0) to pursue this inquiry that will require that CVS Caremark, Express Scripts, OptumRx, Humana, Prime Therapeutics, and MedImpact Healthcare Systems,...
Today's Sponsors
Today's Sponsor